Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Completed No phase listed Observational

Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis

NCT00001912
View directory record Official record
Conditions
Cysticercosis, Cysts, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 4:29 AM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational

Natural History and Functional Status Study of Patients With Lafora Disease

NCT03876522
View directory record Official record
Conditions
Lafora Disease
Interventions
Not listed
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
5 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

NCT00310375
View directory record Official record
Conditions
Epilepsy
Interventions
Ezogabine: USAN Retigabine (International Nonproprietary Name)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of New Fitting Characteristics for Extended Wear Hearing Aid Technology

NCT05274165
View directory record Official record
Conditions
Hearing Loss
Interventions
Lyric Hearing Aid- Experimental Design, Lyric Hearing Aid- Commercially Available
Device
Lead sponsor
Sonova AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 21, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Ketogenic Diet for Child Epilepsy and Seizure Control

NCT00004729
View directory record Official record
Conditions
Epilepsy, Seizures, Lennox-Gastaut Syndrome
Interventions
Ketogenic diet
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Year to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2006 · Synced Oct 21, 2026, 4:29 AM EDT
Not yet recruiting Phase 3 Interventional

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

NCT07220902
View directory record Official record
Conditions
Severe Preeclampsia, Eclampsia Preeclampsia
Interventions
Levetiracetam, magnesium sulfate
Drug
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Tolerability and Efficacy of Depakote-extended Release in the Elderly

NCT00318929
View directory record Official record
Conditions
Elderly, Epilepsy, Seizures
Interventions
Divalproex Sodium Extended-Release Tablets
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
60 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Comorbidities in Epilepsy Using Eye Movement Recordings

NCT06310772
View directory record Official record
Conditions
Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
Interventions
Not listed
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment Outcomes of ReACT for PNES

NCT02801136
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT, Supportive Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 21, 2026, 4:29 AM EDT
Enrolling by invitation No phase listed Observational

Study of Direct Brain Recording and Stimulation for Memory Enhancement

NCT04095026
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

NCT01999777
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Assessing Fitting Guides in Alcon Multifocal Contact Lenses

NCT03118934
View directory record Official record
Conditions
Presbyopia, Refractive Errors
Interventions
Lotrafilcon B multifocal contact lenses, Nelfilcon A multifocal contact lenses, Delefilcon A multifocal contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
40 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
14
States / cities
Phoenix, Arizona • San Diego, California • Pensacola, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

NCT00152516
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
levetiracetam (LEV)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 16 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 21, 2026, 4:29 AM EDT
Completed No phase listed Observational

Epilepsy Impact Scale

NCT01833234
View directory record Official record
Conditions
Epilepsy
Interventions
Interviews and questionnaires
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Apioc Presbyopic Contact Lens

NCT04437732
View directory record Official record
Conditions
Presbyopia, Refractive Errors
Interventions
Apioc-P and Apioc-PT Contact Lens Design
Device
Lead sponsor
Lentechs, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Athens, Ohio • Powell, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 21, 2026, 4:29 AM EDT
Not listed Not applicable Interventional

Study to Validate Novel Seizure-Detection Algorithm

NCT04291716
View directory record Official record
Conditions
Seizures, Motor, Seizures, Seizure Disorder, Epilepsy, Epileptic Seizures, Epileptic
Interventions
Motor Seizure Detection Algorithm (mSDA)
Device
Lead sponsor
Overwatch Digital Health
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 21, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 21, 2026, 4:29 AM EDT